1104 related articles for article (PubMed ID: 32993622)
21. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
[TBL] [Abstract][Full Text] [Related]
22. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.
Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637
[TBL] [Abstract][Full Text] [Related]
23. Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point.
Rogosnitzky M; Berkowitz E; Jadad AR
JMIR Public Health Surveill; 2020 May; 6(2):e19199. PubMed ID: 32374264
[TBL] [Abstract][Full Text] [Related]
24. COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?
Aleksova A; Ferro F; Gagno G; Cappelletto C; Santon D; Rossi M; Ippolito G; Zumla A; Beltrami AP; Sinagra G
J Intern Med; 2020 Oct; 288(4):410-421. PubMed ID: 32459372
[TBL] [Abstract][Full Text] [Related]
25. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
26. Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status.
Beeraka NM; Sadhu SP; Madhunapantula SV; Rao Pragada R; Svistunov AA; Nikolenko VN; Mikhaleva LM; Aliev G
Front Immunol; 2020; 11():552925. PubMed ID: 33072093
[TBL] [Abstract][Full Text] [Related]
27. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Giovane RA; Rezai S; Cleland E; Henderson CE
Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
[TBL] [Abstract][Full Text] [Related]
28. Combating devastating COVID-19 by drug repurposing.
Pawar AY
Int J Antimicrob Agents; 2020 Aug; 56(2):105984. PubMed ID: 32305589
[TBL] [Abstract][Full Text] [Related]
29. Repurposing old drugs as antiviral agents for coronaviruses.
Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
[TBL] [Abstract][Full Text] [Related]
30. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019: Friend or Foe?
Shyh GI; Nawarskas JJ; Cheng-Lai A
Cardiol Rev; 2020; 28(4):213-216. PubMed ID: 32496364
[TBL] [Abstract][Full Text] [Related]
31. Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.
Wang JJ; Edin ML; Zeldin DC; Li C; Wang DW; Chen C
Pharmacol Ther; 2020 Nov; 215():107628. PubMed ID: 32653530
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression.
Sinha S; Cheng K; Schäffer AA; Aldape K; Schiff E; Ruppin E
Mol Syst Biol; 2020 Jul; 16(7):e9628. PubMed ID: 32729248
[TBL] [Abstract][Full Text] [Related]
33. COVID-19 and androgen-targeted therapy for prostate cancer patients.
Bhowmick NA; Oft J; Dorff T; Pal S; Agarwal N; Figlin RA; Posadas EM; Freedland SJ; Gong J
Endocr Relat Cancer; 2020 Sep; 27(9):R281-R292. PubMed ID: 32508311
[TBL] [Abstract][Full Text] [Related]
34. Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19.
Kumar S; Zhi K; Mukherji A; Gerth K
Viruses; 2020 Apr; 12(5):. PubMed ID: 32357553
[TBL] [Abstract][Full Text] [Related]
35. The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future.
Zhang J; Wang M; Ding W; Wan J
Life Sci; 2020 Sep; 257():118142. PubMed ID: 32712300
[TBL] [Abstract][Full Text] [Related]
36. Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety.
Akhtar S; Benter IF; Danjuma MI; Doi SAR; Hasan SS; Habib AM
J Drug Target; 2020; 28(7-8):683-699. PubMed ID: 32700580
[TBL] [Abstract][Full Text] [Related]
37. Network Controllability-Based Prioritization of Candidates for SARS-CoV-2 Drug Repositioning.
Ackerman EE; Shoemaker JE
Viruses; 2020 Sep; 12(10):. PubMed ID: 32993136
[TBL] [Abstract][Full Text] [Related]
38. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
[TBL] [Abstract][Full Text] [Related]
39. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
Sternberg A; McKee DL; Naujokat C
Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679
[TBL] [Abstract][Full Text] [Related]
40. Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.
Vázquez-Cornejo E
Bol Med Hosp Infant Mex; 2020; 77(5):274-281. PubMed ID: 33064690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
